


## Curriculum Vitae

<b>Name</b>	<b>Jee Hyun Kim</b>	
<b>Current Position &amp; Affiliation</b>	<b>Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine</b>	
<b>Country</b>	<b>Republic of Korea</b>	

### Educational Background

2002 – 2004	Ph.D. in Internal Medicine, Seoul National University, Graduate School, Republic of Korea
2000 – 2002	M.S. in Internal Medicine, Seoul National University, Graduate School, Republic of Korea
1989 – 1995	M.D. degree from Seoul National University College of Medicine, Republic of Korea

### Professional Experience

2019 – current	Director, Precision Medicine Center, Seoul National University Bundang Hospital
2017- 2020	Director, Clinical Trial Center, Seoul National University Bundang Hospital
2015- current	Professor, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Republic of Korea
2011-2016	Chief, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital
2009-2015	Associate Professor, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Republic of Korea

2008-2009	Visiting professor, Division of molecular and cellular oncology, Department of Medical Oncology, Dana Farber Cancer Institute, U.S
2003-2008	Assistant Professor, Seoul National University Bundang Hospital, Republic of Korea

### Professional Organizations

Korean Society of Medical Oncology, Director without portfolio  
Korean Cancer Study Group, Chair, Planning Committee  
Korean Precision Medicine Networking Group, Leader  
Korean Cancer Association  
ASCO, AACR, SIOG

### Main Scientific Publications

1. Lee HJ, Kim KJ, Sung JH, Nam M, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, **Kim JH**. PI3K p110 $\alpha$  Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells *Cancers (Basel)* 2020 Sep 3;12(9):2500.
2. Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, **Kim JH**. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer. *Breast Cancer Res Treat.* 2020 Jul 26. doi: 10.1007/s10549-020-05811-2
3. Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. *Oncologist.* 2020 Mar;25(3):e502-e511
4. Kim SH, Kim JW, Hwang IG, Jang JS, Hong S, Kim TY, Baek JY, Shin SH, Sun S, Hong DS, Kim HJ, Hong YS, Woo IS, Lee JH, **Kim JH**. Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. *J Geriatr Oncol.* 2019 Sep;10(5):749-756.
5. Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, Lee KH, **Kim JH**. Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. *Cancer Res Treat.* 2019 Jul;51(3):1249-1256

6. Lee YG, Lee JH, Kim SH, Kim YJ, Lee H, Ahn S, Jang JS, Lee JS, **Kim JH**. Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study. *Lung Cancer*. 2018 Aug;122:88-93.
  7. Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Kim SY, Nam BH, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Bae SH, Koo DH, Kim KI, **Kim JH**. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. *Br J Cancer*. 2018 May;118(9):1169-1175.
  8. Suh KJ, Kim SH, Lee KH, Kim TY, Kim YJ, Han SW, Kang E, Kim EK, Kim K, No JH, Han W, Noh DY, Lee M, Kim HS, Im SA, **Kim JH**. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. *Cancer Res Treat*. 2017 Oct;49(4):1153-1163.
  9. Kim JW, Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YI, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, **Kim JH**, Kim TW. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. *Oncologist*. 2017 Mar;22(3):293-303.
  10. Kim SH, Jung KH, Kim TY, Im SA, Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ, Lee S, Sohn JH, Park YH, Im YH, Ahn JH, Kim SB, **Kim JH**. Prognostic Value of Axillary Nodal Ratio After Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide (AC) Followed by Docetaxel (DOC) in breast cancer: A Multicenter Retrospective Cohort Study. *Cancer Res Treat*. 2016 Oct;48(4):1373-1381.
-